Pain control and reduction of opioid use with OMIDRIA

Post author:

#OMIDRIA

This prospective study demonstrated that patients treated with OMIDRIA had a statistically significant lower use of fentanyl intraoperatively while also experiencing significantly less pain than those treated with epinephrine.

Trending publications / white papers

Publication / Delivering a Dropless Pathway in Cataract Surgery

Kourtney Houser and John Hovanesian discuss how dropless therapy regimens with OMIDRIA® equal – and...

#OMIDRIA

Publication / Blocking the Inflammatory Cascade

Dr. Donnenfeld sheds light on the myriad of benefits of integrating OMIDRIA in cataract...

#OMIDRIA

Publication / Controlling postoperative inflammation and associated complications with OMIDRIA

Dr. Visco discusses the surgical and patient benefits of continuous intracameral administration of OMIDRIA.

#OMIDRIA

Related publications / white papers

Publication / Delivering a Dropless Pathway in Cataract Surgery

Kourtney Houser and John Hovanesian discuss how dropless therapy regimens with OMIDRIA® equal – and can potentially exceed – the current standard of care in cataract surgery regimens.

#OMIDRIA

Publication / Blocking the Inflammatory Cascade

Dr. Donnenfeld sheds light on the myriad of benefits of integrating OMIDRIA in cataract surgery, encompassing a reduced postoperative drop regimen and an enhanced patient journey.

#OMIDRIA

Publication / Making Cataract Surgery Child’s Play

Dr. Wilson shares his study results demonstrating that OMIDRIA is safe for use in children and maintained mydrias during cataract surgery.

#OMIDRIA

INDICATIONS AND USAGE

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.